Search
Search Results
##search.searchResults.foundPlural##
-
CYTOMEGALOVIRUS REACTIVATION IN ADULT RECIPIENTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
1597PDF: 932HTML: 1019figures: 214table 1: 211table2: 212table3: 218 -
The ASSOCIATED FACTORS ON CYTOMEGALOVIRUS REACTIVATION OF CRITICALLY ILL IMMUNOCOMPETENT PATIENTS Cytomegalovirus Reactivation of Critically Ill Patients.
215PDF: 203HTML: 17 -
MANAGEMENT OF HBV INFECTION DURING IMMUNOSUPPRESIVE TREATMENT
893PDF: 499HTML: 1313 -
LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B
3870PDF: 1651HTML: 865Figures . Eliassian: 256 -
Glucocorticoids and antivirals for HBV reactivation in onco-hematologic patients
1031PDF: 589HTML: 2224Cover Letter: 217 -
HEPATITIS B AND C IN HEMATOPOIETIC STEM CELL TRANSPLANT
1032PDF: 559HTML: 743 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
4373Suppl. Files: 1223PDF: 1134Html: 275 -
IMMUNOLOGY OF TUBERCULOSIS
5795PDF: 2151HTML: 7362Untitled: 217 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1534PDF: 1375HTML: 115 -
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS. Anti-CMV immunoglobulins for CMV treatment
2663PDF: 1225HTML: 284 -
-
TARGETING DORMANT BACILLI TO FIGHT TUBERCULOSIS
3173PDF: 1056HTML: 3194 -
Status Epilepticus Due to Severe HHV-6 Encephalitis in an Allogeneic Stem Cell Transplant Recipient
1235PDF: 867HTML: 2193Figue 1: 193 -
PARASITIC INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
3820PDF: 1310HTML: 3932Untitled: 261Untitled: 293 -
-
Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis.
1834PDF: 587HTML: 16996Figure 4: 194Figure 3: 164Figure 2: 170Figure 1: 206 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3572PDF: 1433HTML: 2724 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4937PDF: 1862HTML: 2867Untitled: 254 -
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT
1626PDF: 1073HTML: 143 -
TUBERCULOSIS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES
3439PDF: 1290HTML: 8397 -
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
1780PDF: 830HTML: 883jdoe, table 2 infections CML .doc: 219jdoe, table 1 infections CML .doc: 205 -
TUBERCULOSIS IN TROPICAL AREAS AND IMMIGRANTS
3470PDF: 1373HTML: 6345 -
Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure Memory Cell Population Of Natural Killer Cells in COVID-19 and Cytomegalovirus Exposure
1299PDF: 975HTML: 347 -
HHVs AND LYMPHOPROLIFERATIVE DISORDERS
1478PDF: 860HTML: 3138







